Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus (Globe Newswire)

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it is exploring the potential of using NP-120 (Ifenprodil) as a novel treatment for COVID-19, also known as the coronavirus. A recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with H5N1 infected mice. H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate.

Based on this study, published by the American Society of Microbiology in mSystems in the December 2019 issue, the company believes that Ifenprodil has the potential to be a front-line treatment for the most severe cases of coronavirus, and may also reduce morbidity in patients. Coronavirus currently has an overall predicted mortality rate of approximately 4%. Management’s belief that Ifenprodil is a possible treatment for COVID-19 is based on historic animal studies and not on human trials.

Learn more about Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus.
X